Josh Fink

Luma Group is a next-generation investment firm focused on the intersection of biology and computation. We back breakthrough science by investing in pioneering life sciences companies driving the future of medicine, biotechnology, and human health, powered by AI and advanced analytics, that has the potential to radically improve human health and longevity. Our focus is on transformative technologies in biotech: • Game changing therapies that can redefine treatment paradigms • AI/ML-driven drug discovery platforms accelerating time from bench to bedside • Disease detection and monitoring tools that personalize and optimize care • Smart devices and diagnostics with advanced data capture and real-time analysis capabilities Led by seasoned investors and biotech operators, Josh Fink, Dr. Themasap Khan, PhD, and Dr. Jamie Kasuboski, PhD, Luma Group brings together deep scientific expertise, strategic insight, and operational know-how. Our advisory network includes former Fortune 500 executives, biotech founders, policy leaders, and healthcare innovators who’ve built and scaled category-defining companies. At Luma Group, we don’t just fund innovation; we partner with visionary founders to help shape it. We invest in companies with strong intellectual property and differentiated technology that are moving the needle in healthcare and have the potential to solve large, unmet medical needs. Our mission is to support science that matters, unlock untapped markets, and build lasting value for patients, partners, and the future of global health.